Previous 10 | Next 10 |
Simulations Plus press release ( NASDAQ: SLP ): Q1 GAAP EPS of $0.06 misses by $0.03 . Revenue of $11.96M (-3.7% Y/Y) misses by $0.47M . Software revenue decreased 17% to $6.1 million, representing 51% of total revenue; Services revenue increased 17% to $5.9 millio...
Total revenue of $12 million; Diluted Earnings Per Share (EPS) of $0.06; Both in line with fiscal 2023 guidance and Q1 expectations for revenue seasonality shift Provides capital allocation strategy update focusing on corporate development activities, $50 million share repurchase prog...
Simulations Plus ( NASDAQ: SLP ) is scheduled to announce FQ1 earnings results on Wednesday, January 4th, after market close. The consensus EPS Estimate is $0.12 (-20.0% Y/Y) and the consensus Revenue Estimate is $12.43M (+0.1% Y/Y). Over the last 1 year, SLP has beaten EPS ...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...
Conference call to be on Wednesday, January 4, 2023, at 5 p.m. EST Simulations Plus, Inc. (Nasdaq: SLP) announced today that it will report financial results for the first quarter of fiscal year 2023, the period ended November 30, 2022, after the close of the financial markets on Wedn...
Project will focus on the development of a modeling & simulation framework to support an assessment of bioequivalence for locally-acting drugs in the gastrointestinal tract Simulations Plus, Inc . (Nasdaq: SLP), a leading provider of modeling and simulation softw...
Ex-Anvisa General Manager will contribute to global regulatory strategies involving pharmacometrics Simulations Plus, Inc . (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that...
International organization’s mission is to close the gender gap in technology Simulations Plus (Nasdaq: SLP) today announced its final donation in celebration of 25 years in business. During this 25th anniversary year, which commenced in July 2021, teams of lo...
Simulations Plus ( NASDAQ: SLP ) and the University of Florida's College of Pharmacy were awarded a new funded contract from the U.S. Food and Drug Administration (FDA) to advance in vitro and (patho) physiology-based pharmacokinetics (PBPK) models to understand and p...
Collaboration combines novel in vitro experimental methods and mechanistic modeling to accelerate development of orally inhaled drug products (OIDPs) and propose alternative approaches for bioequivalence Simulations Plus, Inc . (Nasdaq: SLP), a leading provider of mo...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...